{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T16:23:59Z","timestamp":1780331039637,"version":"3.54.1"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.humpath.2023.05.006","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T11:39:57Z","timestamp":1684409997000},"page":"12-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Diagnostic utility of PRAME immunohistochemistry in PEComa family of tumors and morphologic mimics with emphasis on the gynecologic tract"],"prefix":"10.1016","volume":"138","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6706-0700","authenticated-orcid":false,"given":"Marie C.","family":"Smithgall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Liu-Jarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamaljeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ruhul","family":"Quddus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adela","family":"Cimic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2023.05.006_bib1","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1097\/PAS.0000000000000470","article-title":"Incidental nodal lymphangioleiomyomatosis is not a harbinger of pulmonary lymphangioleiomyomatosis: a study of 19 cases with evaluation of diagnostic immunohistochemistry","volume":"39","author":"Schoolmeester","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2023.05.006_bib2","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/gcc.22908","article-title":"Perivascular epithelioid cell tumors (PEComa) of the gynecologic tract","volume":"60","author":"Bennett","year":"2021","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.humpath.2023.05.006_bib3","article-title":"Female genital tumours","year":"2020"},{"key":"10.1016\/j.humpath.2023.05.006_bib4","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1097\/PAS.0000000000001134","article-title":"PRAME expression in melanocytic tumors","volume":"42","author":"Lezcano","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2023.05.006_bib5","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1097\/PAS.0000000000001944","article-title":"PRAME expression in cancer. A systematic immunohistocheical study of >5800 epithelial and nonepithelial tumors","volume":"46","author":"Kaczorwski","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2023.05.006_bib6","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/DAD.0000000000002128","article-title":"PRAME expression in challenging dermal melanocytic neoplasms and soft tissue tumors with melanocytic differentiation","volume":"44","author":"Kline","year":"2022","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.humpath.2023.05.006_bib7","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1074-7613(00)80426-4","article-title":"Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor","volume":"6","author":"Ikeda","year":"1997","journal-title":"Immunity"},{"key":"10.1016\/j.humpath.2023.05.006_bib8","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1046\/j.1365-2141.1998.00982.x","article-title":"PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells","volume":"102","author":"van Baren","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.humpath.2023.05.006_bib9","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2005.07.003","article-title":"The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling","volume":"122","author":"Epping","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.humpath.2023.05.006_bib10","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/cjp2.16","article-title":"Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma","volume":"1","author":"Iura","year":"2015","journal-title":"J Pathol Clin Res"},{"key":"10.1016\/j.humpath.2023.05.006_bib11","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/pin.12565","article-title":"Soft tissue sarcomas: from a morphological to a molecular biological approach","volume":"67","author":"Oda","year":"2017","journal-title":"Pathol Int"},{"key":"10.1016\/j.humpath.2023.05.006_bib12","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.bbrc.2012.02.110","article-title":"Expression and prognostic relevance of PRAME in primary osteosarcoma","volume":"419","author":"Tan","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.humpath.2023.05.006_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2016-000068","article-title":"Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study","volume":"1","author":"Gutzmer","year":"2016","journal-title":"ESMO Open"},{"key":"10.1016\/j.humpath.2023.05.006_bib14","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1016\/j.jtho.2016.08.120","article-title":"Safety and immunogenicity of the PRAME cancer immunotherapeutic in patients with resected non-small cell lung cancer: a phase I dose escalation study","volume":"11","author":"Pujol","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.humpath.2023.05.006_bib15","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/CJI.0b013e3182280db1","article-title":"A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors","volume":"34","author":"Weber","year":"2011","journal-title":"J Immunother"},{"key":"10.1016\/j.humpath.2023.05.006_bib16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13569-017-0077-3","article-title":"Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes","volume":"15","author":"Roszik","year":"2017","journal-title":"Clin Sarcoma Res"},{"key":"10.1016\/j.humpath.2023.05.006_bib17","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12770","article-title":"The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer","volume":"53","author":"Xu","year":"2020","journal-title":"Cell Prolif"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004681772300117X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004681772300117X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T16:41:09Z","timestamp":1758645669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004681772300117X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":17,"alternative-id":["S004681772300117X"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2023.05.006","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnostic utility of PRAME immunohistochemistry in PEComa family of tumors and morphologic mimics with emphasis on the gynecologic tract","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2023.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}